Sarepta Therapeutics Balance Sheet - Annual (NASDAQ:SRPT)

Add to My Stocks
$30.38 $1.7 (5.93%) SRPT stock closing price Feb 22, 2017 (Closing)

The Sarepta Therapeutics balance sheet is a snapshot of the company's financial health at a given point of time, whereas the other two financial statements are for a particular accounting period. Financial strength can be guaged by performing Sarepta Therapeutics stock analysis and by analyzing the balance sheet. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Sarepta Therapeutics had a long term debt of $14.96M at the end of 2015. Sarepta Therapeutics operating cash flow was $-149.46M while Sarepta Therapeutics revenue stood at $1.25M. View latest and last 10 year balance sheet data to check Sarepta Therapeutics financial performance..

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Marketable Securities122.88M136.79M7.25M---0.17M0.28M0.27M
Raw Materials---------
Work In Progress---------
Finished Goods---------
Notes Receivable---------
Other Current Assets17.38M35.03M3.06M1.53M1.64M1.02M0.77M0.59M0.76M
Sarepta Therapeutics Total Current Assets
Property Plant & Equipment61.93M58.39M32.37M20.1M20.03M17.03M16.49M18.1M18.64M
Accumulated Depreciation24.59M19.89M17.32M16.7M15.76M14.96M14.02M12.91M11.81M
Sarepta Therapeutics Net Property Plant & Equipment
Investment & Advances0.78M0.78M0.64M------
Other Non-Current Assets-----1.96M2.37M--
Deferred Charges--------3.06M
Deposits & Other Assets4.47M2.06M0.02M2.77M0.15M0.12M0.12M0.03M0.03M
Sarepta Therapeutics Total Assets
Notes Payable2.49M2.49M-------
Accounts Payable20.23M12.4M17.63M7.53M9.39M1.31M1.38M2.01M3.02M
Current Portion Long-Term Debt5.93M0.09M0.09M0.08M0.08M0.08M0.07M0.07M0.07M
Current Portion Capital Leases---------
Accrued Expenses29.05M17.36M5.04M2.74M2.24M2.01M0.92M1.3M1.17M
Income Taxes Payable---------
Other Current Liabilities4.57M4.5M13.19M68.52M8.87M42.45M31.12M3.89M5.48M
Sarepta Therapeutics Total Current Liabilities
Deferred Taxes/Income6.17M6.77M6.83M------
Convertible Debt---------
Long-Term Debt14.96M3.73M1.57M1.66M1.75M1.84M1.92M2M2.07M
Non-Current Capital Leases---------
Other Long-Term Liabilities---0.76M0.99M1.09M0.96M0.51M0.43M
Sarepta Therapeutics Total Liabilities
Minority Interest---------
Preferred Stock---------
Common Stock Net0.01M---0.01M0.01M0.01M0.01M0.01M
Capital Surplus1.09B926.76M790.42M554.92M340.96M304.81M299.08M266.03M252.73M
Retained Earnings-899.05M-679.02M-543.23M-431.25M-309.96M-307.64M-275.46M-250.31M-226.35M
Treasury Stock---------
Other Liabilities-0.11M-0.09M-------
Sarepta Therapeutics Shareholders Equity
Sarepta Therapeutics Total Liabilities & Shareholders Equity
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Balance sheet for another ticker

Looking at Sarepta Therapeutics historical stock prices and the current Sarepta Therapeutics stock price can tell you how the stock price has moved, whereas the Sarepta Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:
  • Assets: An asset is a resource that a corporation like Sarepta Therapeutics owns and has monetary significance. SRPT assets decreased from $295.03M in 2014 to $273.78M in 2015 . Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Sarepta Therapeutics's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for SRPT stock stand at $83.43M.

Sarepta Therapeutics Balance Sheet - Key Ratios

Current ratio
Debt to Equity ratio

Annual Balance Sheets For Sarepta Therapeutics Inc Peers

Aviragen Therapeutics balance sheet, AveXis balance sheet, BioCryst Pharma balance sheet, Gilead Sciences balance sheet, Halozyme Therapeutics balance sheet